Osteoarthritis Injectable Market: Care Delivery, Access, and Demographics Shaping Adoption
The osteoarthritis injectable market is shaped as much by how and where treatment is delivered as by the therapies themselves. Polaris Market Research estimates the market at USD 8.30 billion in 2025, rising to USD 15.15 billion by 2034 at a CAGR of 7.0% during 2026β2034. North America was the largest market in 2025. Underlying demand reflects a growing need for non-surgical pain management among an aging population. According to ISPOR, global osteoarthritis prevalence reached 8.13% in 2023.
Outpatient Orthopedic Centers Improve Access
The expansion of outpatient orthopedic centersΒ is improving treatment access and procedure volumes. These centers offer fast, convenient osteoarthritis treatment without long hospital stays. In October 2025, Hospital for Special Surgery and General Atlantic created a nationwide outpatient care network to improve access to orthopedic and spinal care through outpatient surgery centers, which provide image-guided injections, rehabilitation assistance, and day-of-discharge care.
Patients prefer faster procedures, shorter waiting times, and lower treatment costs compared with hospital-based care. Ambulatory centers are increasing adoption of image-guided injections and same-day treatment models, which supports market access, repeat treatments, and growth opportunities for injectable therapy companies and specialty clinics.
Hip Osteoarthritis as a Growth Area
While the knee segment is the largest by anatomy, hip osteoarthritis is expected to grow at the highest CAGR during the forecast period. The report attributes this to rising diagnosis rates and a growing preference for early non-surgical intervention, with improving imaging-guided injection procedures supporting adoption. Higher demand for mobility care is also aiding growth. In February 2025, Seikagaku Corporation initiated Phase III clinical trials in Japan for Gel-One, a treatment for osteoarthritis in the knee and hip regions.
The Role of Hospital Pharmacies
Hospital pharmacies dominated the end-user segment in 2025 with a 48.5% revenue share, supported by advanced imaging systems, skilled surgeons, and hybrid operating rooms. Higher patient admissions drove demand, and large hospitals remain key centers for complex procedures. Demand also comes from orthopedic practices, pain management centers, and ambulatory clinics, and increasing capital expenditure in biologics, imaging support, and sports medicine practices has helped drive adoption. North America's lead reflects its developed orthopedic system and high acceptance of injection therapy.
Demographics Sustain Treatment Volumes
Senior citizens are more likely to experience cartilage degeneration, joint stiffening, and impaired mobility, which enlarges the patient pool and increases demand for musculoskeletal services. Europe holds a substantial market share, supported by efficient healthcare facilities and growing demand for non-invasive treatment. Eurostat reports that the EU population reached 450.6 million in January 2025, with 22.0% aged 65 and above.
Asia Pacific is the fastest-growing region at a CAGR of 7.7% during the forecast period, driven by a rising elderly population and improving access to orthopedic care in China, India, Japan, and South Korea.
ππ±π©π₯π¨π«π ππ‘π ππ¨π¦π©π₯πππ ππ¨π¦π©π«ππ‘ππ§π¬π’π―π πππ©π¨π«π πππ«π :
https://www.polarismarketresearch.com/industry-analysis/osteoarthritis-injectable-marketΒ
Cost Barriers and the Value Chain
Increasing healthcare expenditure, obesity, and patient education are additional growth drivers, and rising prevalence is lifting demand for corticosteroid injections, hyaluronic acid injections, and regenerative injections. Even so, expensive biologic injection therapies deter use in economies that cannot afford them, and little or no insurance reimbursement for treatments such as platelet-rich plasma and stem cell therapy limits patient uptake.
The value chain spans product innovation, drug testing, FDA approval, manufacturing, purchase from hospitals and clinics, medical administration, and post-treatment follow-up. The main aim is to reduce pain, improve joint movement, and extend the life of affected joints.
Key Players
Leading companies include Sanofi S.A., Bioventus Inc., Fidia Farmaceutici S.p.A., Ferring Pharmaceuticals A/S, Anika Therapeutics, Inc., Pacira BioSciences, Inc., Paradigm Biopharmaceuticals Ltd., Merck KGaA, Biosplice Therapeutics, Inc., Novartis AG, Smith & Nephew plc, and Globus Medical, Inc. Competitive approaches include expanding regenerative offerings, building collaborations with clinics, and widening distribution channels and regional coverage.
Taken together, outpatient access, hospital capacity, and demographics shape how the osteoarthritis injectable market will continue to evolve.
Conclusion
The osteoarthritis injectable market is expected to experience continued development as the prevalence of osteoarthritis increases among aging populations. Growing demand for non-surgical treatment options is encouraging the adoption of corticosteroids, hyaluronic acid injections, and other emerging therapies. Advances in regenerative medicine and biologic treatments are creating new opportunities for product innovation. Increasing awareness of joint health and improvements in healthcare access are also supporting market demand. Nevertheless, treatment costs, variable clinical outcomes, and concerns regarding long-term effectiveness may limit adoption. Overall, continued research and the development of improved injectable therapies are expected to shape the market's future.
More Trending Latest Reports By Polaris Market Research:
Cell & Gene Therapy Bioanalytical Testing Services Market